The DALI vitamin D randomized controlled trial for gestational diabetes mellitus prevention: No major benefit shown besides vitamin D sufficiency.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Linear or logistic regression analyses were performed to assess intervention effects.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

The DALI vitamin D multicenter study enrolled women with prepregnancy body mass index (BMI) ≥ 29 kg/m2, ≤19 + 6 weeks of gestation and without GDM.

How the Study Was Run

The design is described as randomized, placebo-controlled and multicenter.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes, Gestational, Dietary Supplements, Europe, Insulin, Vitamin D and Vitamins.

The authors tagged it with the keywords Fasting plasma glucose, Fasting plasma insulin, Gestational diabetes mellitus, Pregnancy, Vitamin D sufficiency and Vitamin D supplementation.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and multicenter study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.